Voyager Therapeutics, Inc. - stock earnings
VYGR Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2024 AfterMarket | - / -0.4488000000 | - | - / 9.6 million | - |
VYGR Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q3 | -25.9 million USD | 4.6 million USD |
| 2023Q2 | -22.2 million USD | 4.9 million USD |
| 2023Q1 | 124.0 million USD | 150.5 million USD |
| 2022Q4 | -23.6 million USD | -41.1 million USD |
| 2022Q3 | 17.6 million USD | 41.1 million USD |
| 2022Q2 | -18.9 million USD | 712000 USD |
| 2022Q1 | -21.3 million USD | 658000 USD |
| 2021Q4 | 5.7 million USD | 28.1 million USD |
| 2021Q3 | -25.1 million USD | 1.5 million USD |
| 2021Q2 | -30.1 million USD | 1.4 million USD |
| 2021Q1 | -21.6 million USD | 6.5 million USD |
| 2020Q4 | -15.9 million USD | 6.5 million USD |
| 2020Q3 | 85.6 million USD | 117.8 million USD |
| 2020Q2 | -8.7 million USD | 28.7 million USD |
| 2020Q1 | -24.3 million USD | 18.1 million USD |
| 2019Q4 | -12.6 million USD | 32.7 million USD |
| 2019Q3 | -15.0 million USD | 20.4 million USD |
| 2019Q2 | 11.2 million USD | 46.1 million USD |
| 2019Q1 | -27.2 million USD | 5.2 million USD |
| 2018Q4 | -22.5 million USD | 2.0 million USD |
| 2018Q3 | -20.3 million USD | 2.1 million USD |
| 2018Q2 | -25.5 million USD | 2.6 million USD |
| 2018Q1 | -19.9 million USD | 942000 USD |
| 2017Q4 | -11.8 million USD | 6.3 million USD |
| 2017Q3 | -23.3 million USD | 1.1 million USD |
| 2017Q2 | -18.9 million USD | 1.2 million USD |
| 2017Q1 | -16.6 million USD | 1.5 million USD |
| 2016Q4 | -14.7 million USD | 2.4 million USD |
| 2016Q3 | -9.0 million USD | 3.3 million USD |
| 2016Q2 | -9.3 million USD | 3.7 million USD |
| 2016Q1 | -7.2 million USD | 4.8 million USD |
| 2015Q4 | -7.3 million USD | 4.9 million USD |
| 2015Q3 | -3.9 million USD | 4.9 million USD |
| 2015Q2 | -3.9 million USD | 4.9 million USD |
| 2015Q1 | -14.6 million USD | 2.6 million USD |
| 2014Q4 | -4.7 million USD | ? USD |
| 2014Q3 | -4.0 million USD | ? USD |
VYGR Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 52.3 million USD | 158.4 million USD |
| 2022 | -46.4 million USD | 40.9 million USD |
| 2021 | -66.0 million USD | 37.4 million USD |
| 2020 | 36.7 million USD | 171.1 million USD |
| 2019 | -40.8 million USD | 104.4 million USD |
| 2018 | -88.3 million USD | 7.6 million USD |
| 2017 | -70.7 million USD | 10.1 million USD |
| 2016 | -40.2 million USD | 14.2 million USD |
| 2015 | -29.7 million USD | 17.3 million USD |
| 2014 | -16.3 million USD | ? USD |
VYGR
Price: $8.81
52 week price:
Earnings Per Share: 2.97 USD
P/E Ratio: 6.42
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 275000
Ebitda: -22.9 millionMarket Capitalization: 479.5 million